Secondary Logo

C-101 Production and properties of SOSIP trimers

Moore, John, PhD

JAIDS Journal of Acquired Immune Deficiency Syndromes: April 2018 - Volume 77 - Issue - p 37
doi: 10.1097/01.qai.0000532588.51931.24
Abstracts: PDF Only

I will review the progress of our team's projects to produce GMP-quality SOSIP trimers in amounts and quantities appropriate for human clinical trials. The BG505 SOSIP.664 GMP-project has now been completed successfully, yielding ~5 g of trimers. A follow-up on effort to make the germline–bNAb targeting BG505 SOSIP. v4.1-GT1.1 trimer is well underway, using the same core methodologies. The latter trimer was designed at the Amsterdam Medical Center and is very similar to one recently described by Medina-Ramirez et al in J Exp Med.

This project stems from our NIH-funded HIVRAD grant program and the translation phase has been supported and managed by the BMGF and IAVI, reflecting the three funding agencies working together towards a common goal.

Weill Cornell Medicine

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.